TABLE 4
Determination of CYP Clint of individual human CYPs to oxidative metabolism for marker substrates

Compound CLint
CYP1A2 CYP2C9 CYP2C19 CYP2D6 CYP3A4
µl · min-1pmol-1
Tolbutamide N.D.a 0.014b 0.03  ± 0.01 N.D. N.D.
Diazepam N.D. N.D. 0.17  ± 0.05 N.D. N.D.
Metoprolol N.D. N.D. N.D. 1.03  ± 0.07 N.D.
Ibuprofen N.D. 0.29 ± 0.09 0.17  ± 0.01 N.D. N.D.
Propranolol 0.34 ± 0.03 N.D. 0.66  ± 0.06 5.07  ± 2.80 N.D.
Dextromethorphan N.D. N.D. 0.16  ± 0.10 1.97  ± 0.24 N.D.
Omeprazole N.D. N.D. 6.95  ± 1.93 N.D. 0.44  ± 0.06
Diltiazem N.D. N.D. 0.30  ± 0.04 N.D. 0.58  ± 0.04
Testosterone N.D. N.D. N.D. N.D. 0.42  ± 0.03
Verapamil N.D. N.D. N.D. N.D. 1.19  ± 0.12
a  N.D., not detectable (<0.02 µl · min-1 · pmol-1).
b  Determined from Vmax/Km. Mean ± S.D. for n = 3 separate experiments.